Literature DB >> 11166885

Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting.

Z Q Yao1, G Gallez-Hawkins, N A Lomeli, X Li, K M Molinder, D J Diamond, J A Zaia.   

Abstract

The major target of human cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) is the tegument protein CMVpp65. However, this protein has protein kinase (PK) activity, and the unknown effects on cell replication of an exogenous PK in healthy cells could limit the use of CMVpp65 as a vaccine, especially in children. In this report we show that a point mutation converting lysine to asparagine at the invariant lysine (K436), an essential site for phosphotransfer, abolishes the threonine kinase activity. The mutant CMVpp65 maintains its immunologic target characteristics, including antibody and CTL reactivity. This kinase-deficient CMVpp65 is a candidate for evaluation in future CMV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166885     DOI: 10.1016/s0264-410x(00)00423-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Viral serine/threonine protein kinases.

Authors:  Thary Jacob; Céline Van den Broeke; Herman W Favoreel
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

2.  Biologic and immunologic effects of knockout of human cytomegalovirus pp65 nuclear localization signal.

Authors:  John A Zaia; Xiuli Li; Anne E Franck; Xiwei Wu; Lia Thao; Ghislaine Gallez-Hawkins
Journal:  Clin Vaccine Immunol       Date:  2009-04-15

3.  Human cytomegalovirus phosphoproteins are hypophosphorylated and intrinsically disordered.

Authors:  Franz J J Rieder; Marie-Theres Kastner; Markus Hartl; Martin G Puchinger; Martina Schneider; Otto Majdic; William J Britt; Kristina Djinović-Carugo; Christoph Steininger
Journal:  J Gen Virol       Date:  2017-04-01       Impact factor: 3.891

Review 4.  Tegument proteins of human cytomegalovirus.

Authors:  Robert F Kalejta
Journal:  Microbiol Mol Biol Rev       Date:  2008-06       Impact factor: 11.056

Review 5.  VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection.

Authors:  Mark R Schleiss
Journal:  Curr Opin Mol Ther       Date:  2009-10

6.  Cytomegalovirus pp65 limits dissemination but is dispensable for persistence.

Authors:  Daniel Malouli; Scott G Hansen; Ernesto S Nakayasu; Emily E Marshall; Colette M Hughes; Abigail B Ventura; Roxanne M Gilbride; Matthew S Lewis; Guangwu Xu; Craig Kreklywich; Nathan Whizin; Miranda Fischer; Alfred W Legasse; Kasinath Viswanathan; Don Siess; David G Camp; Michael K Axthelm; Christoph Kahl; Victor R DeFilippis; Richard D Smith; Daniel N Streblow; Louis J Picker; Klaus Früh
Journal:  J Clin Invest       Date:  2014-04-01       Impact factor: 14.808

7.  Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus.

Authors:  Jie Zhong; Michael Rist; Leanne Cooper; Corey Smith; Rajiv Khanna
Journal:  PLoS One       Date:  2008-09-22       Impact factor: 3.240

8.  Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates.

Authors:  Aimin Tang; Daniel C Freed; Fengsheng Li; Steve Meschino; Michael Prokop; Andrew Bett; Danilo Casimiro; Dai Wang; Tong-Ming Fu
Journal:  Hum Vaccin Immunother       Date:  2017-05-11       Impact factor: 3.452

9.  Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial.

Authors:  Larry R Smith; Mary K Wloch; Jennifer A Chaplin; Michele Gerber; Alain P Rolland
Journal:  Vaccines (Basel)       Date:  2013-09-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.